1 story in the last 7 days
The latest phase 4 trial news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks phase 4 trial across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Alpha Cognition enrolled the first patient in RESOLVE, a Phase 4 post-marketing study evaluating ZUNVEYL in mild to moderate Alzheimer's disease. The study will collect safety and tolerability data and explore changes in neuropsychiatric symptoms in an outpatient setting. Approximately 150 patients will be enrolled across multiple clinical sites.
Summaries by ByteBrief